Funder: Pfizer Inc.
Due Dates: June 12, 2026: Full application submission deadline (applications must be submitted by 23:59 Eastern Standard Time, e.g., New York, GMT -5)
Funding Amounts: Up to $200,000 per project (smaller requests around $50,000 encouraged); maximum $250,000 with strong justification; up to 10 projects funded.
Summary: Supports independent real-world research on elranatamab in relapsed/refractory multiple myeloma, focusing on safety, effectiveness, and care delivery in diverse populations.
Key Information: Applications submitted after the deadline will not be reviewed; only organizations in China, France, Germany, Italy, Japan, Spain, Turkey, and the UK are eligible.